Deoxyribonucleotides As Determinants of DNA Replication Fidelity in Bacteriophage T4
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Nucleotide Metabolism
NUCLEOTIDE METABOLISM General Overview • Structure of Nucleotides Pentoses Purines and Pyrimidines Nucleosides Nucleotides • De Novo Purine Nucleotide Synthesis PRPP synthesis 5-Phosphoribosylamine synthesis IMP synthesis Inhibitors of purine synthesis Synthesis of AMP and GMP from IMP Synthesis of NDP and NTP from NMP • Salvage pathways for purines • Degradation of purine nucleotides • Pyrimidine synthesis Carbamoyl phosphate synthesisOrotik asit sentezi • Pirimidin nükleotitlerinin yıkımı • Ribonükleotitlerin deoksiribonükleotitlere dönüşümü Basic functions of nucleotides • They are precursors of DNA and RNA. • They are the sources of activated intermediates in lipid and protein synthesis (UDP-glucose→glycogen, S-adenosylmathionine as methyl donor) • They are structural components of coenzymes (NAD(P)+, FAD, and CoA). • They act as second messengers (cAMP, cGMP). • They play important role in carrying energy (ATP, etc). • They play regulatory roles in various pathways by activating or inhibiting key enzymes. Structures of Nucleotides • Nucleotides are composed of 1) A pentose monosaccharide (ribose or deoxyribose) 2) A nitrogenous base (purine or pyrimidine) 3) One, two or three phosphate groups. Pentoses 1.Ribose 2.Deoxyribose •Deoxyribonucleotides contain deoxyribose, while ribonucleotides contain ribose. •Ribose is produced in the pentose phosphate pathway. Ribonucleotide reductase converts ribonucleoside diphosphate deoxyribonucleotide. Nucleotide structure-Base 1.Purine 2.Pyrimidine •Adenine and guanine, which take part in the structure -
2'-Deoxyguanosine Toxicity for B and Mature T Lymphoid Cell Lines Is Mediated by Guanine Ribonucleotide Accumulation
2'-deoxyguanosine toxicity for B and mature T lymphoid cell lines is mediated by guanine ribonucleotide accumulation. Y Sidi, B S Mitchell J Clin Invest. 1984;74(5):1640-1648. https://doi.org/10.1172/JCI111580. Research Article Inherited deficiency of the enzyme purine nucleoside phosphorylase (PNP) results in selective and severe T lymphocyte depletion which is mediated by its substrate, 2'-deoxyguanosine. This observation provides a rationale for the use of PNP inhibitors as selective T cell immunosuppressive agents. We have studied the relative effects of the PNP inhibitor 8- aminoguanosine on the metabolism and growth of lymphoid cell lines of T and B cell origin. We have found that 2'- deoxyguanosine toxicity for T lymphoblasts is markedly potentiated by 8-aminoguanosine and is mediated by the accumulation of deoxyguanosine triphosphate. In contrast, the growth of T4+ mature T cell lines and B lymphoblast cell lines is inhibited by somewhat higher concentrations of 2'-deoxyguanosine (ID50 20 and 18 microM, respectively) in the presence of 8-aminoguanosine without an increase in deoxyguanosine triphosphate levels. Cytotoxicity correlates instead with a three- to fivefold increase in guanosine triphosphate (GTP) levels after 24 h. Accumulation of GTP and growth inhibition also result from exposure to guanosine, but not to guanine at equimolar concentrations. B lymphoblasts which are deficient in the purine salvage enzyme hypoxanthine guanine phosphoribosyltransferase are completely resistant to 2'-deoxyguanosine or guanosine concentrations up to 800 microM and do not demonstrate an increase in GTP levels. Growth inhibition and GTP accumulation are prevented by hypoxanthine or adenine, but not by 2'-deoxycytidine. -
United States Patent Office Patented Oct
3,346,562 United States Patent Office Patented Oct. 10, 1967 2 3,346,562 cg METHOD FOR THE PRODUCTION OF PO-CE Base RBONUCLEOSDE-5'-PHOSPHATE / O Mikio Honjo, Takatsuki, and Ryuji Maremoto, Minoo, Cl EO Japan, assignors to Takeda Chemical industries, Ltd., Osaka, Japan No Drawing. Filed May 31, 1966, Ser. No. 553,718 Claims priority, application Japan, May 29, 1965, R. X R. 40/31,814 9 Claims. (Cl. 260-21.5) HO. O. BIO O 10 N1 N1 This invention is concerned with a method for the pro Po-H, Base Po-H, Base duction of ribonucleoside-5'-phosphate. EIO k" wE+ EO k". Ribonucleoside-5'-phosphate is very useful as condi H HO - ment for food and also in the pharmaceutical industry, O O OH OH and has been chemically produced by at first protecting 15 X the hydroxyl groups at the 2'- and 3'-positions of its ribose R1 R2 moiety with acyl or isopropylidene groups and then phos phorylating the 5'-hydroxyl group of the thus-protected RN compound with pentavalent phosphorus compound such C=O: aliphatic ketone or aromatic aldehyde as phosphorus pentachloride, phosphorus oxychloride, 20 R?2 etc., followed by removing the protecting groups. As "ribonucleoside' in the present method there are However, this hitherto-known method requires a long used those containing purine base such as adenosine, time (about 7 to about 30 hours) for completing the pro inosine, etc. or those containing pyrimidine base such as tection and phosphorylation, and therefore is not desirable uridine, cytidine, etc. As the aliphatic ketone having 3 from an industrial viewpoint. -
Genetic Variation in Phosphodiesterase (PDE) 7B in Chronic Lymphocytic Leukemia: Overview of Genetic Variants of Cyclic Nucleotide Pdes in Human Disease
Journal of Human Genetics (2011) 56, 676–681 & 2011 The Japan Society of Human Genetics All rights reserved 1434-5161/11 $32.00 www.nature.com/jhg ORIGINAL ARTICLE Genetic variation in phosphodiesterase (PDE) 7B in chronic lymphocytic leukemia: overview of genetic variants of cyclic nucleotide PDEs in human disease Ana M Peiro´ 1,2, Chih-Min Tang1, Fiona Murray1,3, Lingzhi Zhang1, Loren M Brown1, Daisy Chou1, Laura Rassenti4, Thomas A Kipps3,4 and Paul A Insel1,3,4 Expression of cyclic adenosine monophosphate-specific phosphodiesterase 7B (PDE7B) mRNA is increased in patients with chronic lymphocytic leukemia (CLL), thus suggesting that variation may occur in the PDE7B gene in CLL. As genetic variation in other PDE family members has been shown to associate with numerous clinical disorders (reviewed in this manuscript), we sought to identify single-nucleotide polymorphisms (SNPs) in the PDE7B gene promoter and coding region of 93 control subjects and 154 CLL patients. We found that the PDE7B gene has a 5¢ non-coding region SNP À347C4T that occurs with similar frequency in CLL patients (1.9%) and controls (2.7%). Tested in vitro, À347C4T has less promoter activity than a wild-type construct. The low frequency of this 5¢ untranslated region variant indicates that it does not explain the higher PDE7B expression in patients with CLL but it has the potential to influence other settings that involve a role for PDE7B. Journal of Human Genetics (2011) 56, 676–681; doi:10.1038/jhg.2011.80; published online 28 July 2011 Keywords: cAMP; chronic lymphocytic -
Nucleotide Metabolism 22
Nucleotide Metabolism 22 For additional ancillary materials related to this chapter, please visit thePoint. I. OVERVIEW Ribonucleoside and deoxyribonucleoside phosphates (nucleotides) are essential for all cells. Without them, neither ribonucleic acid (RNA) nor deoxyribonucleic acid (DNA) can be produced, and, therefore, proteins cannot be synthesized or cells proliferate. Nucleotides also serve as carriers of activated intermediates in the synthesis of some carbohydrates, lipids, and conjugated proteins (for example, uridine diphosphate [UDP]-glucose and cytidine diphosphate [CDP]- choline) and are structural components of several essential coenzymes, such as coenzyme A, flavin adenine dinucleotide (FAD[H2]), nicotinamide adenine dinucleotide (NAD[H]), and nicotinamide adenine dinucleotide phosphate (NADP[H]). Nucleotides, such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), serve as second messengers in signal transduction pathways. In addition, nucleotides play an important role as energy sources in the cell. Finally, nucleotides are important regulatory compounds for many of the pathways of intermediary metabolism, inhibiting or activating key enzymes. The purine and pyrimidine bases found in nucleotides can be synthesized de novo or can be obtained through salvage pathways that allow the reuse of the preformed bases resulting from normal cell turnover. [Note: Little of the purines and pyrimidines supplied by diet is utilized and is degraded instead.] II. STRUCTURE Nucleotides are composed of a nitrogenous base; a pentose monosaccharide; and one, two, or three phosphate groups. The nitrogen-containing bases belong to two families of compounds: the purines and the pyrimidines. A. Purine and pyrimidine bases Both DNA and RNA contain the same purine bases: adenine (A) and guanine (G). -
De Novo Deoxyribonucleotide Biosynthesis Regulates Cell Growth
www.nature.com/scientificreports OPEN De novo deoxyribonucleotide biosynthesis regulates cell growth and tumor progression in small‑cell lung carcinoma Ami Maruyama1,2,3, Yuzo Sato1,2,4,5, Joji Nakayama1,2,3, Junko Murai4,5, Takamasa Ishikawa5,6, Tomoyoshi Soga4,5 & Hideki Makinoshima1,2,3,7* Deoxyribonucleotide biosynthesis from ribonucleotides supports the growth of active cancer cells by producing building blocks for DNA. Although ribonucleotide reductase (RNR) is known to catalyze the rate‑limiting step of de novo deoxyribonucleotide triphosphate (dNTP) synthesis, the biological function of the RNR large subunit (RRM1) in small‑cell lung carcinoma (SCLC) remains unclear. In this study, we established siRNA‑transfected SCLC cell lines to investigate the anticancer efect of silencing RRM1 gene expression. We found that RRM1 is required for the full growth of SCLC cells both in vitro and in vivo. In particular, the deletion of RRM1 induced a DNA damage response in SCLC cells and decreased the number of cells with S phase cell cycle arrest. We also elucidated the overall changes in the metabolic profle of SCLC cells caused by RRM1 deletion. Together, our fndings reveal a relationship between the deoxyribonucleotide biosynthesis axis and key metabolic changes in SCLC, which may indicate a possible link between tumor growth and the regulation of deoxyribonucleotide metabolism in SCLC. Small-cell lung carcinoma (SCLC) is a neuroendocrine tumor subtype of lung cancer, and it is associated with a poor prognosis1–3. In particular, SCLC is characterized by early and widespread metastatic dissemination and a remarkable response to chemotherapy that is almost invariably followed by the development of drug resistance4. -
Effects of Allopurinol and Oxipurinol on Purine Synthesis in Cultured Human Cells
Effects of allopurinol and oxipurinol on purine synthesis in cultured human cells William N. Kelley, James B. Wyngaarden J Clin Invest. 1970;49(3):602-609. https://doi.org/10.1172/JCI106271. Research Article In the present study we have examined the effects of allopurinol and oxipurinol on thed e novo synthesis of purines in cultured human fibroblasts. Allopurinol inhibits de novo purine synthesis in the absence of xanthine oxidase. Inhibition at lower concentrations of the drug requires the presence of hypoxanthine-guanine phosphoribosyltransferase as it does in vivo. Although this suggests that the inhibitory effect of allopurinol at least at the lower concentrations tested is a consequence of its conversion to the ribonucleotide form in human cells, the nucleotide derivative could not be demonstrated. Several possible indirect consequences of such a conversion were also sought. There was no evidence that allopurinol was further utilized in the synthesis of nucleic acids in these cultured human cells and no effect of either allopurinol or oxipurinol on the long-term survival of human cells in vitro could be demonstrated. At higher concentrations, both allopurinol and oxipurinol inhibit the early steps ofd e novo purine synthesis in the absence of either xanthine oxidase or hypoxanthine-guanine phosphoribosyltransferase. This indicates that at higher drug concentrations, inhibition is occurring by some mechanism other than those previously postulated. Find the latest version: https://jci.me/106271/pdf Effects of Allopurinol and Oxipurinol on Purine Synthesis in Cultured Human Cells WILLIAM N. KELLEY and JAMES B. WYNGAARDEN From the Division of Metabolic and Genetic Diseases, Departments of Medicine and Biochemistry, Duke University Medical Center, Durham, North Carolina 27706 A B S TR A C T In the present study we have examined the de novo synthesis of purines in many patients. -
Antiviral Defense Via Nucleotide Depletion in Bacteria
bioRxiv preprint doi: https://doi.org/10.1101/2021.04.26.441389; this version posted April 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Antiviral defense via nucleotide depletion in bacteria Nitzan Tal1, Adi Millman1, Avigail Stokar-Avihail1, Taya Fedorenko1, Azita Leavitt1, Sarah Melamed1, Erez Yirmiya1, Carmel Avraham1, Gil Amitai1, Rotem Sorek1,# 1 Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel # Corresponding author: [email protected] Abstract DNA viruses and retroviruses need to consume large quantities of deoxynucleotides (dNTPs) when replicating within infected cells. The human antiviral factor SAMHD1 takes advantage of this vulnerability in the viral life cycle, and inhibits viral replication by degrading dNTPs into their constituent deoxynucleosides and inorganic phosphate. In this study we report that bacteria employ a similar strategy to defend against phage infection. We found a family of defensive dCTP deaminase proteins that, in response to phage infection, convert dCTP into deoxy-uracil nucleotides. A second family of phage resistance genes encode dGTPase enzymes, which degrade dGTP into phosphate-free deoxy- guanosine (dG) and are distant homologs of the human SAMHD1. Our results show that the defensive proteins completely eliminate the specific deoxynucleotide (either dCTP or dGTP) from the nucleotide pool during phage infection, thus starving the phage of an essential DNA building block and halting its replication. Both defensive genes are found in a diverse set of bacterial species and are specifically enriched in Vibrio genomes. Our study demonstrates that manipulation of the deoxynucleotide pool is a potent antiviral strategy shared by both prokaryotes and eukaryotes. -
1/05661 1 Al
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date _ . ... - 12 May 2011 (12.05.2011) W 2 11/05661 1 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/00 (2006.0 1) C12Q 1/48 (2006.0 1) kind of national protection available): AE, AG, AL, AM, C12Q 1/42 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 10/054171 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 26 October 2010 (26.10.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/255,068 26 October 2009 (26.10.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, MYREXIS, INC. -
Competitive Inhibition of Beef Heart Cyclic AMP Phosphodiesterase by Cytokinins and Related Compounds (Cyclic AMP Metabolism/Intracellular Cyclic AMP Concentration)
Proc. Nat. Acad. Sci. USA Vol. 71, No. 12, pp. 4670-4674, December 1974 Competitive Inhibition of Beef Heart Cyclic AMP Phosphodiesterase by Cytokinins and Related Compounds (cyclic AMP metabolism/intracellular cyclic AMP concentration) SIDNEY M. HECHT*, ROBERT D. FAULKNER, AND S. D. HAWRELAK Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Mass. 02139 Communicated by Nelson J. Leonard, September 9, 1974 ABSTRACT Two cytokinins and four related analogs, also shown to contain detectable adenylate cyclase activity, none of which is a cyclic ribonucleotide, have been shown suggesting that the cytokinins might function by raising the to act as competitive inhibitors of the high Km cyclic-AMP phosphodiesterase (3': 5'-cyclic-AMP 5'-nucleotidohydro- intracellular level of cyclic AMP (18). If operative in mouse lase, EC 3.1.4.1-7) activity from beef heart. Weak inhibition fibroblasts this phenomenon might also explain the observed of the low Km cyclic AMP phosphodiesterase activity was growth inhibition of such cells by cytokinins (S. M. Hecht and also observed, suggesting a possible mechanism for regula- R.. B. Frye, in preparation), since it has been shown that there tion of intracellular cyclic AMP levels by the exogenously added compounds. In addition to the kinetic data, ob- is an inverse relationship between intracellular cyclic AMP tained on the six inhibitors in four different heterocyclic concentration and growth in fibroblasts (19). series, 15 other cytokinins and related compounds have To further explore the apparent involvement of exogenously been shown to inhibit the high Km cyclic AMP phospho- added cytokinins in cyclic AMP metabolism, we have in- diesterase activity at single concentrations of substrate vestigated the kinetics of interaction of certain cytokinins, and and inhibitor. -
Download Product Insert (PDF)
PRODUCT INFORMATION Guanosine Item No. 27702 CAS Registry No.: 118-00-3 Synonyms: Guanine Ribonucleoside, NSC 19994 N O MF: C10H13N5O5 FW: 283.2 N O OH Purity: ≥98% N N UV/Vis.: λmax: 254 nm Supplied as: A crystalline solid H OH OH H N Storage: -20°C 2 Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Guanosine is supplied as a crystalline solid. A stock solution may be made by dissolving the guanosine in the solvent of choice, which should be purged with an inert gas. Guanosine is soluble in the organic solvent DMSO at a concentration of approximately 30 mg/ml. Guanosine is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, guanosine should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Guanosine has a solubility of approximately 0.16 mg/ml in a 1:5 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Guanosine is a purine nucleoside that is comprised of the purine base guanine attached to a ribose moiety.1 Mono-, di-, tri-, and cyclic monophosphorylated forms of guanosine (GMP, GDP, GTP, and cGMP, respectively) are essential for a variety of endogenous biochemical processes, such as signal transduction, metabolism, and RNA synthesis.2-4 References 1. Voet, D. and Voet, J.G. 3rd ed., John Wiley & Sons, Hoboken, NJ (2004). 2. Hanson, R.W. and Garber, A.J. -
Oxidative Stress and the Guanosine Nucleotide Triphosphate Pool: Implications for a Biomarker and Mechanism of Impaired Cell Function
University of Montana ScholarWorks at University of Montana Graduate Student Theses, Dissertations, & Professional Papers Graduate School 2008 OXIDATIVE STRESS AND THE GUANOSINE NUCLEOTIDE TRIPHOSPHATE POOL: IMPLICATIONS FOR A BIOMARKER AND MECHANISM OF IMPAIRED CELL FUNCTION Celeste Maree Bolin The University of Montana Follow this and additional works at: https://scholarworks.umt.edu/etd Let us know how access to this document benefits ou.y Recommended Citation Bolin, Celeste Maree, "OXIDATIVE STRESS AND THE GUANOSINE NUCLEOTIDE TRIPHOSPHATE POOL: IMPLICATIONS FOR A BIOMARKER AND MECHANISM OF IMPAIRED CELL FUNCTION" (2008). Graduate Student Theses, Dissertations, & Professional Papers. 728. https://scholarworks.umt.edu/etd/728 This Dissertation is brought to you for free and open access by the Graduate School at ScholarWorks at University of Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact [email protected]. OXIDATIVE STRESS AND THE GUANOSINE NUCLEOTIDE TRIPHOSPHATE POOL: IMPLICATIONS FOR A BIOMARKER AND MECHANISM OF IMPAIRED CELL FUNCTION By Celeste Maree Bolin B.A. Chemistry, Whitman College, Walla Walla, WA 2001 Dissertation presented in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Toxicology The University of Montana Missoula, Montana Spring 2008 Approved by: Dr. David A. Strobel, Dean Graduate School Dr. Fernando Cardozo-Pelaez,